Featured News
614Wire StoriesConfluent and Alibaba Cloud Announce Partnership to set Data in Motion in Mainland China
SINGAPORE–(BUSINESS WIRE)–Confluent, Inc. (NASDAQ: CFLT), the platform for data in motion, and Alibaba Cloud, the digital technology and intelligence backbone of Alibaba...
- 714Wire Stories
GLIDE: End of Malaria and Lymphatic Filariasis in Sight for Philippines, Says Award-winning Filipino Doctor
? Dr Fe Esperanza Espino is one of five winners selected to win a Falcon Award for Disease Elimination ? She will...
- 577News
Leading Cosmetics Brand Pula Enters the Chinese Market
TOKYO, JAPAN – Media OutReach – 13 December 2021 – Recently, Pula, a well-known Japanese cosmetics brand for children, has enters the Chinese market,...
- 672Wire Stories
Understanding the Hehe Culture and A Community of Shared Future for Mankind in Taizhou, Zhejiang
TAIZHOU, China–(BUSINESS WIRE)–Themed “Hehe Culture and A Community of Shared Future for Mankind”, the 2021 Hehe Culture Global Forum was held in...
- 1.2KWire Stories
BeiGene Presents Results from SEQUOIA Trial of BRUKINSA (zanubrutinib) in First-Line Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
BRUKINSA demonstrated superiority in progression-free survival over chemoimmunotherapy as a first-line treatment for patients with chronic lymphocytic leukemia Consistent efficacy was observed...
- 693News
Digital Entertainment Leadership Forum’s flagship event on second day
APRU MetaGame Conference focused on education, talent, and the future of esports HONG KONG SAR – Media OutReach – 12 December 2021...
- 894Wire Stories
Valemetostat Pivotal Data Shows Promising Response Rates in Patients with Adult T-Cell Leukemia/Lymphoma
Oral presentation at ASH 2021 features positive phase 2 data in Japanese patients with relapsed/refractory ATL Orphan Drug Designation granted with regulatory...
- 790Wire Stories
BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell Malignancies
Follow-up results from Phase 2 trial suggested intolerable adverse events leading to discontinuation of previous BTK inhibitor therapy were unlikely to recur...
- 584Wire Stories
Rare Element Resources Announces Results of Oversubscribed Rights Offering of Common Shares
LITTLETON, Colo.–(BUSINESS WIRE)–Rare Element Resources Ltd. (the “Company” or “RER”) (OTCQB: REEMF) is pleased to report that its previously announced rights offering...
- 688News
SunMirror AG: Expanding the Team to Support the Execution of the Growth Strategy into Critical Raw Materials
ZUG, SWITZERLAND – EQS Newswire – 11 December 2021 – SunMirror AG (“SunMirror”, “the Company”; Vienna Stock Exchange: ROR1; Frankfurt Stock Exchange: ROR;...
- 640Wire Stories
CTO Realty Growth Completes Sale of the Remaining Daytona Beach Land Within Its Land Joint Venture
DAYTONA BEACH, Fla., Dec. 10, 2021 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced the...
